...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease
【24h】

The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease

机译:中医配方福芳 - 珍珠 - 蒂基保护心肌免受糖尿病患者患有冠心病的伤害

获取原文
获取原文并翻译 | 示例

摘要

Background andpurpose: Diabetes mellitus (DM) is a major risk factor for coronary heart disease (CHD). Previous research has reported that the Fufang-Zhenzhu-Tiaozhi (FTZ) formula has obvious effects on the treatment of dyslipidemia and hyperglycemia. In the present study, we intended to establish a convenient DM-CHD model in minipigs and investigated the protective effect of FTZ against myocardial injury and its mechanism. Methods: The DM-CHD model was established by a high- fat/high-sucrose /high- cholesterol diet (HFSCD) combined with balloon injury in the coronary artery. Subsequently, sixteen Wuzhishan minipigs were assigned to three groups: control group, model group, and FTZ group. The model group and FTZ group were given a HFSCD, while the control group was given a normal diet (ND). FTZ was given with meals in the FTZ group. During this time, biochemical parameters, such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein (HDL-C), and fasting blood glucose (FBG), were measured by using testing kits. Insulin (INS) was determined by ELISA, and the homeostasis model assessment index of insulin resistance (HOMA-IR) was calculated to evaluate insulin resistance levels. After FTZ administration, the plasma levels of lactate dehydrogenase (LDH), creatine kinase isoenzyme MB (CK-MB), and cardiac troponin I (cTnI) were measured by using ELISA kits to evaluate myocardial injury. Coronary artery stenosis was analyzed by angio-graphic and HE staining. Myocardial ischemia was assayed with electrocardiogram (ECG). Moreover, cytokines, including interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP), and tumor necrosis factor-alpha (TNF-α), were measured by ELISA kits to assess inflammation. The myocardial tissue was collected, and the pathological morphology was observed by transmission electron microscopy (TEM), HE staining, and Masson staining. Western blots were used to detect the expression of PI3K, AKT, p-AKT, p-NF-κB, and NF-κB. Results: A DM-CHD model in minipigs with glucose-lipid metabolism disorder, coronary artery incrassation and myocardial damage was successfully established through balloon injury in the coronary artery combined with HFSCD. FTZ effectively inhibited coronary artery incrassation and protected the myocardium against injury in DM-CHD minipigs. FTZ decreased proinflammatory cytokine levels and upregulated the protein expression of the PI3K/Akt pathway in the myocardium. Conclusions: A novel DM-CHD model in minipigs was successfully established through balloon injury in the coronary artery combined with HFSCD. FTZ has a protective effect against myocardial injury in DM-CHD by inhibiting inflammation and activating the PI3K/AKT signaling pathway.
机译:背景与目的:糖尿病(DM)是冠心病(CHD)的主要危险因素。已有研究报道,复方珍珠调脂方对血脂异常和高血糖有明显的治疗作用。本研究旨在建立一种简便的小型猪DM-CHD模型,并探讨FTZ对心肌损伤的保护作用及其机制。方法:采用高脂/高糖/高胆固醇饮食(HFSCD)结合冠状动脉球囊损伤建立糖尿病-冠心病模型。随后,将16头五指山小型猪分为三组:对照组、模型组和FTZ组。模型组和FTZ组给予HFSCD,而对照组给予正常饮食(ND)。FTZ组在用餐时给予FTZ。在此期间,使用检测试剂盒测量生化参数,如总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白(HDL-C)和空腹血糖(FBG)。采用ELISA法测定胰岛素(INS),计算胰岛素抵抗稳态模型评估指数(HOMA-IR)以评估胰岛素抵抗水平。FTZ给药后,用ELISA试剂盒检测血浆乳酸脱氢酶(LDH)、肌酸激酶同工酶MB(CK-MB)和心肌肌钙蛋白I(cTnI)水平,以评估心肌损伤。冠状动脉狭窄通过血管造影和HE染色进行分析。用心电图(ECG)检测心肌缺血。此外,通过ELISA试剂盒测量细胞因子,包括白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)和肿瘤坏死因子-α(TNF-α),以评估炎症。收集心肌组织,用透射电镜(TEM)、HE染色和Masson染色观察病理形态。结果:通过冠状动脉球囊损伤合并HFSCD,成功建立了糖脂代谢紊乱、冠状动脉增厚和心肌损伤的小型猪DM-CHD模型。FTZ能有效抑制DM-CHD小型猪冠状动脉增厚,保护心肌免受损伤。FTZ降低促炎细胞因子水平,上调心肌中PI3K/Akt通路的蛋白表达。结论:通过冠状动脉球囊损伤联合HFSCD成功建立了一种新型的小型猪DM-CHD模型。FTZ通过抑制炎症和激活PI3K/AKT信号通路对DM-CHD心肌损伤具有保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号